Article Text

Download PDFPDF

FRI0372 The ducas: proposal for a digital ulcer assessment score in scleroderma
  1. C Bruni1,
  2. T Ngcozana2,
  3. F Braschi1,
  4. S Guiducci1,
  5. S Bellando-Randone1,
  6. YA Suliman3,
  7. J Grotts4,
  8. CP Denton2,
  9. DE Furst5,
  10. M Matucci-Cerinic1
  1. 1Department of Experimental and Clinical Medicine, Division of Rheumatology, University of Florence, Firenze, Italy
  2. 2Centre for Rheumatology and Connective Tissue Diseases, UCL Division of Medicine, London, United Kingdom
  3. 3Rheumatology and Rehabilitation Department, Assiut University Hospital, Assiut, Egypt
  4. 4Department of Biostatistic
  5. 5Division of Rheumatology, Department of Medicine, University of California at Los Angeles, Los Angeles, United States


Background No objective measure is presently available to assess digital ulcer (DU) in SSc patients apart from “healed/non healed” and experience-based clinical judgment.

Objectives The aim of the current study is to propose a composite DU clinical assessment score (DUCAS) and, to lend it, test its face validity by correlating it with commonly used disease related patient-reported outcomes (PROs) and physician evaluation.

Methods SSc patients presenting at least one DU and attending the Rheumatology Wound Care Clinic of the Florence University Hospital or the London Royal Free Hospital were enrolled. Patients were assessed with HAQ-DI, Cochin scale, Visual analogic scale (VAS) for DU-related pain (DU_pain, 0–100 mm), patient VAS for global DU status (ptGDU, 0–100mm) and patient global assessment (PtGA, 0–100 mm) as PROs and physician VAS for DU status (phyGDU, 0–100mm). The DUCAS included 7 DU related variables selected by a committee of 8 SSc DU experts - they are outlined in figure 1. Each variable was weighted on a clinical basis and the DUCAS score was the sum of the values for the 7 variables (max=19.5). Spearman's correlation tests were calculated for to examine face validity. A linear regression model with forward and backward stepwise analysis was used to determine the relationship of individual variables with the primary clinical parameter, phyGDU.

Results 44 SSc patients (9 males, mean age 54,3±15,6 years, mean disease duration 9,9±5,8 years) were enrolled in the study. Mean phyGDU was 44,3±23mm, mean ptGDU was 54±30mm (Wilcoxon p=0.022, phyGDU VAS vs ptGDU) and mean DUCAS score was 4,2±2. Overall DUCAS showed significant positive correlations with all PROs, but when all the individual clinician and patient's variables were modelled, only the overall DUCAS significantly predicted PhyGDU; after backwards stepwise analysis overall DUCAS and ptGDU best predicted PhyGDU, with an adjusted R2=0,437 and AIC=380,3 (Table 2).

Table 1

Conclusions DUCAS is a newly proposed clinical score for SSc related DU which has face validity and which may reflect DU status as judged by SSc experts. Further validation of this score will be undertaken.

Acknowledgements Cosimo Bruni received a EULAR travel bursary to run this project in the UK.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.